High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Abstract Background As older age and having certain comorbidities can influence humoral responses to vaccination, we studied antibody responses after the COVID-19 booster campaigns in nursing home (NH) residents. Methods In a two year longitudinal study with Dutch NH residents (n = 107), aged 50 yea...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2025-01-01
|
| Series: | Immunity & Ageing |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12979-024-00495-4 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1841559109650874368 |
|---|---|
| author | Marloes I Hofstee Joanna Kaczorowska Abigail Postema Erna Zomer Maren van Waalwijk Gustaaf Jonathans Lia GH de Rond Gaby Smits Lotus L van den Hoogen Gerco den Hartog Anne-Marie Buisman |
| author_facet | Marloes I Hofstee Joanna Kaczorowska Abigail Postema Erna Zomer Maren van Waalwijk Gustaaf Jonathans Lia GH de Rond Gaby Smits Lotus L van den Hoogen Gerco den Hartog Anne-Marie Buisman |
| author_sort | Marloes I Hofstee |
| collection | DOAJ |
| description | Abstract Background As older age and having certain comorbidities can influence humoral responses to vaccination, we studied antibody responses after the COVID-19 booster campaigns in nursing home (NH) residents. Methods In a two year longitudinal study with Dutch NH residents (n = 107), aged 50 years and over, we monitored antibody responses in serum prior to and after vaccination with a third, fourth BNT162b2 (wild-type; WT), and a BNT162b2 bivalent (WT/OMI BA.1) fifth vaccine. Data on vaccinations, infections, comorbidities, and, for some participants, clinical symptoms after infection were obtained with questionnaires. Data were compared to antibody responses of BNT162b2-vaccinated, healthier community-dwelling older adults (n = 32) from the general population. Results The booster vaccinations substantially increased anti-WT and anti-Omicron SARS-CoV-2 Spike S1 (S1) and Spike protein receptor binding domain (RBD)-antibody concentrations of NH residents. This resulted in comparable antibody levels between NH residents and healthier community-dwelling older adults and between infection-naïve and infected NH residents, and in a decline in treatment duration and clinical symptom severity in SARS-CoV-2-infected NH residents. Between one and twelve months after the bivalent fifth dose, anti-Omicron BA.1 antibody levels of the NH residents waned faster than those against the WT strain. Conclusions The booster vaccinations upheld humoral responses of NH residents to WT and Omicron SARS-CoV-2. This, in addition to the less virulent circulating strains, decreased symptom severity and treatment durations for SARS-CoV-2-infected NH residents. Boosting this vulnerable group should, therefore, be continued to prevent waning of humoral immunity and achieve sufficient protection especially against newly emerging variants of concern. |
| format | Article |
| id | doaj-art-f899874c4bdd47ab88c7e0e313280e92 |
| institution | Kabale University |
| issn | 1742-4933 |
| language | English |
| publishDate | 2025-01-01 |
| publisher | BMC |
| record_format | Article |
| series | Immunity & Ageing |
| spelling | doaj-art-f899874c4bdd47ab88c7e0e313280e922025-01-05T12:46:11ZengBMCImmunity & Ageing1742-49332025-01-0122111310.1186/s12979-024-00495-4High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residentsMarloes I Hofstee0Joanna Kaczorowska1Abigail Postema2Erna Zomer3Maren van Waalwijk4Gustaaf Jonathans5Lia GH de Rond6Gaby Smits7Lotus L van den Hoogen8Gerco den Hartog9Anne-Marie Buisman10Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)SurplusSurplusAmstelring, Location Nursing Home BornholmCentre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)Centre for Infectious Disease Control, National Institute for Public Health and the Environment (RIVM)Abstract Background As older age and having certain comorbidities can influence humoral responses to vaccination, we studied antibody responses after the COVID-19 booster campaigns in nursing home (NH) residents. Methods In a two year longitudinal study with Dutch NH residents (n = 107), aged 50 years and over, we monitored antibody responses in serum prior to and after vaccination with a third, fourth BNT162b2 (wild-type; WT), and a BNT162b2 bivalent (WT/OMI BA.1) fifth vaccine. Data on vaccinations, infections, comorbidities, and, for some participants, clinical symptoms after infection were obtained with questionnaires. Data were compared to antibody responses of BNT162b2-vaccinated, healthier community-dwelling older adults (n = 32) from the general population. Results The booster vaccinations substantially increased anti-WT and anti-Omicron SARS-CoV-2 Spike S1 (S1) and Spike protein receptor binding domain (RBD)-antibody concentrations of NH residents. This resulted in comparable antibody levels between NH residents and healthier community-dwelling older adults and between infection-naïve and infected NH residents, and in a decline in treatment duration and clinical symptom severity in SARS-CoV-2-infected NH residents. Between one and twelve months after the bivalent fifth dose, anti-Omicron BA.1 antibody levels of the NH residents waned faster than those against the WT strain. Conclusions The booster vaccinations upheld humoral responses of NH residents to WT and Omicron SARS-CoV-2. This, in addition to the less virulent circulating strains, decreased symptom severity and treatment durations for SARS-CoV-2-infected NH residents. Boosting this vulnerable group should, therefore, be continued to prevent waning of humoral immunity and achieve sufficient protection especially against newly emerging variants of concern.https://doi.org/10.1186/s12979-024-00495-4COVID-19BNT162b2 booster dosesBivalentGeriatricsAntibody responsesOmicron |
| spellingShingle | Marloes I Hofstee Joanna Kaczorowska Abigail Postema Erna Zomer Maren van Waalwijk Gustaaf Jonathans Lia GH de Rond Gaby Smits Lotus L van den Hoogen Gerco den Hartog Anne-Marie Buisman High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents Immunity & Ageing COVID-19 BNT162b2 booster doses Bivalent Geriatrics Antibody responses Omicron |
| title | High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents |
| title_full | High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents |
| title_fullStr | High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents |
| title_full_unstemmed | High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents |
| title_short | High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents |
| title_sort | high sars cov 2 antibody levels after three consecutive bnt162b2 booster vaccine doses in nursing home residents |
| topic | COVID-19 BNT162b2 booster doses Bivalent Geriatrics Antibody responses Omicron |
| url | https://doi.org/10.1186/s12979-024-00495-4 |
| work_keys_str_mv | AT marloesihofstee highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents AT joannakaczorowska highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents AT abigailpostema highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents AT ernazomer highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents AT marenvanwaalwijk highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents AT gustaafjonathans highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents AT liaghderond highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents AT gabysmits highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents AT lotuslvandenhoogen highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents AT gercodenhartog highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents AT annemariebuisman highsarscov2antibodylevelsafterthreeconsecutivebnt162b2boostervaccinedosesinnursinghomeresidents |